GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Calithera Biosciences CALA · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

0.00%

Close of 6 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Calithera Biosciences — daily CALA Delayed
Market value
$487
Last close × shares
Volume
315
Shares, 6 Nov 2026

About Calithera Biosciences

Its shares trade under the ticker CALA. It has been listed since 2 October 2014. In the fiscal year to 31 December 2021, it reported revenue of $9.8m and a net loss of $115.1m. At that date it held total assets of $64.8m and shareholders' equity of $8.4m.

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. The company is headquartered in South San Francisco, California. The company went IPO on 2014-10-02. The firm focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. The company is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The firm's lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors.

Figures and description from our data supplier, not checked against the company's own report.

More about Calithera Biosciences →

How it makes its money

Revenue, year to 31 Dec 2018

  • Collaboration Revenue $31.0m · 139.5%

Latest on Calithera Biosciences

Our reporting

We have not reported on Calithera Biosciences yet.

Next results

17 Nov 2026

Due on 17 Nov 2026. Analysts expect earnings of -5.52 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Calithera Biosciences's ticker?

Calithera Biosciences trades as CALA on its US listing, under ISIN US13089P5070.

What was Calithera Biosciences's last closing price?

0.00 on 6 Nov 2026. The figure is in USD and is never converted.

When does Calithera Biosciences next report results?

Results are expected on 17 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.